FDA Approves BUPRENORPHINE AND NALOXONE — Dr.Reddys Laboratories Inc

Dr. Reddy’s Laboratories Inc. announced the FDA approval of its buccal Buprenorphine and Naloxone tablets, expanding its portfolio in the opioid dependence market with a potentially lower-cost generic alternative. This authorization strengthens Dr. Reddy’s competitive positioning by offering a remedy for patients and payers seeking affordable options amidst rising healthcare costs.